You're receiving this email because you're subscribed to Ring the Bell from Benzinga. To manage your subscription, click the link at the bottom of this email.

Happy Wednesday! Look I’ll be honest, I didn’t watch any of last night’s presidential debate. I was stuck in a different debate with my friends: what’s the difference between cement and concrete?

After two hours, there was no conclusive winner. Speaking of winners, here are the stocks trading higher after the real debate, and how the market reacted to this morning’s CPI data.

—Aaron Bry

Plus, check out the company reshaping educational and medical fields through AI adoption.

MARKET SNAPSHOT

Yesterday: The overall market closed higher, but bank stocks took a hit after a warning from Ally. Oracle was your big winner on the day, closing up more than 10%.

On Our Radar: CPI numbers came out this morning, mostly in line with expectations. The market sold off initially, but ‘buy the dippers’ came in to bring the S&P 500 back in the green ahead of the open.

TOP STORY

Polling Veteran Nate Silver Says Kamala Harris Got The Debate She Wanted

Basically: Vice President Kamala Harris seems to have emerged as the winner of the first presidential debate between her and Republican candidate Donald Trump, and veteran pollster Nate Silver offered his take on the proceedings on Wednesday.

So: The strong consensus is that Harris won the night, said Silver, who founded FiveThirtyEight but is no longer associated with the polling analytics website. Solar and clean energy names are trading higher after the debate, with the $TAN ETF up nearly 4% ahead of Wednesday’s open.

PRESENTED BY AMESITE

How Amesite Is Trailblazing In the AI Market by Adding Healthcare to Its College Business

Amesite (NASDAQ: AMST) is making a name for itself thanks to its AI-powered learning platform. The company just inked its seventh deal with a community college, landing Maricopa Community College District as a customer.  

Maricopa Community Colleges is Arizona’s largest workforce developer, playing a central role in charting the future of the Greater Phoenix region. It produces the second-largest number of college graduates in Arizona and creates one out of every 28 jobs in Maricopa County. Under the deal Maricopa Community College District’s roughly 140,000 students will have access to Amesite’s online training and development platform. 

But that’s not all. Amesite recently expanded into healthcare, rolling out NurseMagic, an AI app geared toward the over five million nurses in the United States. 

The app offers a bevy of capabilities designed to make nurses' lives easier. Since its beta launch in June, user growth has exploded 830% from June to July. Nurses in 50 states and six countries use the app daily. To learn more about Amesite and its AI technology, click here.

FIVE ZINGERS

Losing Its Way?: One analyst is worried that Apple is falling behind competitors like Amazon and Google. Here’s why.

Timing Is Key: Jim Cramer says now is not the time to own oil stocks, but does like this sneaky AI play.

Inside Job: Insiders are taking profits and selling shares at major tech companies like NVIDIA, Alphabet and more.

Tough Crowd: Retailer Vera Bradley is trading down nearly 10% this morning after the company reported worse-than-expected earnings.

Your Chance At $30k Risk-Free: Benzinga's World Championship of Trading is about to take off, and all you have to do is sign up and paper trade for your chance at the prizes.

ONE FOR THE ROAD

Inflation Data Hits Lowest Level Since February 2021 — But One Segment Remains Stubbornly High

Basically: The U.S. annual inflation rate in August fell to its lowest point since February 2021, signaling a further easing of pressure on the cost of goods and services for U.S. consumers.

So: The Consumer Price Index (CPI) saw a cooler-than-anticipated annual headline print in August, cementing convictions for interest rate cuts by the Federal Reserve. But here are the areas where inflation remains high.

PRESENTED BY MIRA PHARMACEUTICALS

The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End

Ketamine holds a lot of promise for treating mental health diseases like depression and PTSD, but the current iteration has limitations. For starters, ketamine often requires intravenous or intranasal administration, which can be inconvenient and impractical for at-home treatment. Additionally, ketamine’s interaction with multiple receptor sites in the brain can lead to unwanted side effects such as dissociation, hallucinations and, in some cases, psychotic symptoms. 

MIRA Pharmaceuticals (NASDAQ: MIRA), a pre-clinical-stage pharmaceutical company is refining ketamine with its novel oral ketamine analog, Ketamir-2.  Ketamir-2 is designed to overcome the challenges of existing ketamine treatments by creating an agent that is more targeted. Ketamir-2 selectively inhibits the NMDA receptor at the PCP-binding site with 30-50 times lower affinity than traditional ketamine. This selective inhibition reduces the risk of dissociation and hallucinations,potentially providing a cleaner, safer therapeutic experience for patients.

MIRA is getting closer to clinical trials, aiming to file an Investigational New Drug (IND) application by the end of the year. To learn more about this breakthrough ketamine compound click here. 

BEFORE YOU GO

Were you forwarded this email? Click here to subscribe.

And be sure to check out our other newsletters:

Future Finance: Where fintech, crypto, and the future of finance collide. Future Finance is a perfect lunch read packed with quick bites for industry enthusiasts. Subscribe here.

Cannabis Daily: A must-read daily briefing for cannabis investors, operators, and enthusiasts. Join our list of industry veterans to jump start your morning. Subscribe here.

Real Estate Weekly: Where we highlight the movers and the losers, the upgrades and the downgrades, the top stories and opportunities in the trillion dollar REIT and real asset industry. Subscribe here.

Mining Weekly: Get an insider's edge with news, analysis, and commentary on what’s shaping the mining and commodities industry that powers the global economy. Subscribe here.

Advisor: Tailor-made for Financial Advisors, this weekly newsletter has industry-specific insights, analysis, and news. Subscribe here.